Ramucirumab is an intravenously administered human monoclonal antibody (IgG1) that selectively binds the extracellular domain of vascular endothelial growth factor receptor 2 (VEGFR2), blocking the...
No takes yet. Share an insight, caveat, or question.
Lara et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: